Rodenticides MarketSize, Share & Industry Analysis, 2026-2034By Active Ingredient TypeBy FormBy ApplicationBy Target SpeciesBy End UserBy Distribution ChannelBy Dispensing MethodBy Pack SizeBy Regulatory Use Class
Full title & scope — all 9 axes with their segments
Rodenticides Market Size, Share & Industry Analysis, By Active Ingredient Type (First-Generation Anticoagulants, Second-Generation Anticoagulants, Non-Anticoagulants, Fertility Control and Biological, Fumigants and Other Chemicals), By Form (Pellets, Blocks, Grain and Whole Bait, Powder and Tracking Dust, Paste and Gel Baits, Liquid Concentrates, Sachets and Soft Baits), By Application (Agriculture and Crop Protection, Livestock and Poultry Farms, Residential and Household, Commercial Buildings, Warehouses and Food Processing, Urban and Public Health Control, Conservation and Island Eradication), By Target Species (Norway Rat, Roof Rat, House Mouse, Field Rodents and Voles, Other Rodent Species), By End User (Professional Pest Control Operators, Farmers and Growers, Households and Consumers, Municipal and Government Agencies, Food and Industrial Facility Operators), By Distribution Channel (Direct to Pest Control Companies, Agricultural and Pest Control Distributors, Retail Stores, Online Retail, Government Tenders), By Dispensing Method (Tamper-Resistant Bait Stations, Loose Bait Placement, Bait Boxes and Covered Trays, Tracking Dust Application, Burrow Application and Fumigation, Aerial and Broadcast Baiting), By Pack Size (Consumer Packs, Professional Packs, Bulk Packs), By Regulatory Use Class (Professional-Only Use, General and Consumer Use, Restricted Use Products, Indoor-Only Use, Outdoor and Agricultural Use), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By Active Ingredient TypeFirst-Generation Anticoagulants · Second-Generation Anticoagulants · Non-Anticoagulants
- 02By FormPellets · Blocks · Grain and Whole Bait
- 03By ApplicationAgriculture and Crop Protection · Livestock and Poultry Farms · Residential and Household
- 04By Target SpeciesNorway Rat · Roof Rat · House Mouse
- 05By End UserProfessional Pest Control Operators · Farmers and Growers · Households and Consumers
- 06By Distribution ChannelDirect to Pest Control Companies · Agricultural and Pest Control Distributors · Retail Stores
- 07By Dispensing MethodTamper-Resistant Bait Stations · Loose Bait Placement · Bait Boxes and Covered Trays
- 08By Pack SizeConsumer Packs · Professional Packs · Bulk Packs
- 09By Regulatory Use ClassProfessional-Only Use · General and Consumer Use · Restricted Use Products
- 10By Region
Market Analysis & Outlook
Rodenticides are chemical and biological products used to kill or control rats, mice and other rodents that damage crops, stored food, buildings and infrastructure, and that carry disease. The category covers anticoagulant and non-anticoagulant baits, fumigants and emerging fertility control products, sold as pellets, blocks, pastes, powders and liquids. Buyers include professional pest control operators, farmers, food and industrial facility operators, municipal agencies and households.
Between 2025 and 2034 the global rodenticides market moves from USD 6.1 billion to USD 9.08 billion, compounding at 4.53% a year. Fifteen years are covered in all, taking in USD 4.85 billion in 2020, USD 5.88 billion in 2024, USD 6.37 billion in 2026 and USD 7.61 billion in 2030.
The active ingredient type mix shifts over the period. Second-Generation Anticoagulants is the largest line in 2025 at USD 3.172 billion, a 52% share, moving to USD 4.448 billion and 48.99% by 2034. Fertility Control and Biological grows fastest at 12.53%, taking its share from 3% to 6%, while First-Generation Anticoagulants grows slowest at 0.5%. Non-Anticoagulants and Fertility Control and Biological take share over the period; First-Generation Anticoagulants, Second-Generation Anticoagulants and Fumigants and Other Chemicals give it up while still growing in absolute terms.
Cut by form, the largest line is Pellets: 28% of 2025 revenue, worth USD 1.708 billion, and 25% at USD 2.27 billion by 2034. Paste and Gel Baits grows faster at 9.33% against 3.21%, moving from 10% of revenue to 15% by 2034. Both this axis and the active ingredient type one divide the same revenue, so they are two views of one total, not parts to be added.
Behind these figures sit five regions, five active ingredient type lines and nine segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- A forecast-period rate of 4.53% takes the market from USD 6.1 billion in 2025 to USD 9.08 billion in 2034, against 4.69% recorded over the 2020-2025 historical period.
- The largest line by active ingredient type is Second-Generation Anticoagulants, worth USD 3.172 billion and 52% of revenue in 2025, rising to USD 4.448 billion and 48.99% by 2034.
- Fertility Control and Biological is the fastest-growing line at 12.53%, lifting its share from 3% in 2025 to 6% in 2034 and its revenue from USD 0.183 billion to USD 0.545 billion.
- Against a base case of USD 9.08 billion in 2034, the study also reports a bear case at USD 7.95 billion and a bull case at USD 10.22 billion, with the assumptions behind each set out separately.
- The United States accounts for 80% of North America in the base year, worth USD 1.22 billion in 2025 and reaching USD 1.6 billion by 2034, the worked country example carried through that region's chapters.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By active ingredient type
Base year 2025Second-Generation Anticoagulants leads with 52.0% of active ingredient type segment revenue.
Share of active ingredient type segment revenue, most recent base year.
Read across the forecast period, the global rodenticides market shows movement in three places: active ingredient type composition, regional weight, and the 4.53% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
The active ingredient type mix tilts toward Fertility Control and Biological. The widest spread on the active ingredient type axis is between Fertility Control and Biological at 12.53% and First-Generation Anticoagulants at 0.5%. Fertility Control and Biological takes its share of revenue from 3% to 6% while First-Generation Anticoagulants gives up ground, from 17% to 12%. In absolute terms Fertility Control and Biological rises from USD 0.183 billion to USD 0.545 billion, while First-Generation Anticoagulants rises from USD 1.037 billion to USD 1.09 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.
Every region grows, none at another's expense. With no share changing hands, each region's trajectory is readable from the global rate, and regional planning becomes a question of capturing growth where it already is.
The series never breaks trajectory. The market moves through USD 4.85 billion in 2020, USD 5.88 billion in 2024, USD 6.1 billion in 2025, USD 6.37 billion in 2026, USD 7.61 billion in 2030 and USD 9.08 billion in 2034. There is no discontinuity to time, and 4.53% forecast growth against 4.69% historical means the trend continues and does not turn. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the active ingredient type and regional sections come in.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
Fertility Control and Biological compounds at 12.53% against 4.53% for the market, rising from USD 0.183 billion in 2025 to USD 0.545 billion in 2034 and from 3% of revenue to 6%. Because the spread to First-Generation Anticoagulants at 0.5% is this wide, the headline 4.53% is a weighted result, not a rate any single line achieves. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02Growth lands where the revenue already is
Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03The trend is already in the record
USD 4.85 billion in 2020, USD 5.88 billion in 2024 and USD 6.1 billion in 2025: 4.69% compound growth before the forecast period even begins. From there the forecast carries 4.53% through to USD 9.08 billion in 2034. Because the growth is already in the record and not only in the projection, the rate is held flat across the forecast instead of ramped, and the risk in the number sits in the mix assumptions, not in whether the market grows at all.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Urban rodent pressure and outsourced pest control | High | +1.45 | High | High | Medium |
| 2 | Grain, food storage and farm loss prevention | Medium-High | +0.95 | High | Medium | Medium |
| 3 | Shift to tamper-resistant stations and professional programmes | Medium | +0.8 | Medium | High | High |
| 4 | Food safety audits and public health programmes | Medium | +0.6 | Medium | Medium | Medium |
| 5 | Others | Low | +0.38 | Low | Low | Low |
| Total | +4.18 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Tightening limits on anticoagulant use and sale | High | −0.72 | Medium | High | High |
| 2 | Resistance, wildlife exposure concerns and shift to trapping | Medium-High | −0.48 | Medium | Medium | High |
| Total | −1.2 | |||||
Drivers contribute 4.18 USD Billion and restraints remove 1.2 USD Billion, a net 2.98 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 4.53% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the active ingredient type axis, and where regional growth is concentrated.
Restraining Factors
What holds the forecast back
Market Restraints
2- 01What holds the forecast back
Major markets impose sharp outdoor and consumer anticoagulant bans, resistance spreads faster than new actives are approved and trapping and exclusion methods take volume from bait. On that assumption 2034 revenue lands at USD 7.95 billion against the USD 9.08 billion base case, from the same USD 6.1 billion 2025 starting point.
- 02Second-Generation Anticoagulants holds the blended rate down
Second-Generation Anticoagulants carries 52% of 2025 revenue at USD 3.172 billion but compounds at 3.83% against 4.53% for the market, taking its share to 48.99% by 2034 even as revenue rises to USD 4.448 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
Anticoagulant registrations stay in place under professional-use conditions, urban infestation pressure keeps rising and non-anticoagulant products gain approvals faster than expected. On that assumption the market reaches USD 10.22 billion by 2034 against USD 9.08 billion in the base case, from the same USD 6.1 billion in 2025.
- 02The opening is on the active ingredient type axis, not the regional one
Share on the active ingredient type axis moves toward Fertility Control and Biological, from 3% in 2025 to 6% in 2034, on 12.53% growth against the market's 4.53% and revenue rising from USD 0.183 billion to USD 0.545 billion. Taking position there does not require displacing whoever holds Second-Generation Anticoagulants, which is the harder and more expensive fight.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
Second-Generation Anticoagulants is 52% of 2025 revenue at USD 3.172 billion and still 48.99% at USD 4.448 billion in 2034. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02The United States is 80% of North America
North America is worth USD 1.525 billion in 2025 and USD 1.22 billion of that is the United States; 80% of the region, reaching USD 1.6 billion in 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
9 axesThe market is divided by active ingredient type and by form, application, target species, end user, distribution channel, dispensing method, pack size and regulatory use class; nine axes in all. Revenue does not add across them: each is a different cut of the same total.
Five active ingredient type lines are reported. Two of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Active Ingredient Type · 5 segments
Second-Generation Anticoagulants Held the Dominant Share of the Active ingredient type Segment in 2025
- Largest Second-Generation Anticoagulants · 52%
- Fastest Fertility Control and Biological · 12.5%
- Moves most First-Generation Anticoagulants · -5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| First-Generation Anticoagulants | $1.04B | 17% | $1.09B | 12%-5 | 0.5% |
| Second-Generation Anticoagulants | $3.17B | 52% | $4.45B | 49%-3 | 3.8% |
| Non-Anticoagulants | $0.73B | 12% | $1.54B | 17%+5 | 8.6% |
| Fertility Control and Biological | $0.18B | 3% | $0.55B | 6%+3 | 12.5% |
| Fumigants and Other Chemicals | $0.98B | 16% | $1.45B | 16% | 4.5% |
Second-generation anticoagulants lead because a single feeding is lethal, which suits professional programmes dealing with populations already resistant to older compounds. Non-anticoagulants and fertility control grow fastest from a small base, pushed by tighter limits on anticoagulant use outdoors and by buyers looking for options with lower risk to non-target wildlife. First-generation products lose share as users trade up. By 2034 Second-Generation Anticoagulants is still ahead, making this a shift in weight, not a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Form · 7 segments
By Form
- Largest Pellets · 28%
- Fastest Paste and Gel Baits · 9.3%
- Moves most Paste and Gel Baits · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pellets | $1.71B | 28% | $2.27B | 25%-3 | 3.2% |
| Blocks | $1.46B | 24% | $2.18B | 24% | 4.5% |
| Grain and Whole Bait | $0.85B | 14% | $1B | 11%-3 | 1.8% |
| Powder and Tracking Dust | $0.43B | 7% | $0.55B | 6%-1 | 2.8% |
| Paste and Gel Baits | $0.61B | 10% | $1.36B | 15%+5 | 9.3% |
| Liquid Concentrates | $0.37B | 6% | $0.55B | 6% | 4.5% |
| Sachets and Soft Baits | $0.67B | 11% | $1.18B | 13%+2 | 6.5% |
2025 to 2034 revenue and share by line: Pellets USD 1.708 billion to USD 2.27 billion (28% to 25%), Blocks USD 1.464 billion to USD 2.179 billion (24% to 24%), Grain and Whole Bait USD 0.854 billion to USD 0.999 billion (14% to 11%), Sachets and Soft Baits USD 0.671 billion to USD 1.18 billion (11% to 13%), Paste and Gel Baits USD 0.61 billion to USD 1.362 billion (10% to 15%), Powder and Tracking Dust USD 0.427 billion to USD 0.545 billion (7% to 6%), Liquid Concentrates USD 0.366 billion to USD 0.545 billion (6% to 6%). Pellets Held the Dominant Share of the Form Segment in 2025 Pellets and blocks lead because they are the standard formats loaded into bait stations and placed in damp or outdoor settings where weather resistance matters. Paste and gel baits grow fastest, helped by their palatability in kitchens, food plants and sewers, and by sachets and soft baits that suit households wanting ready-to-use, low-handling products. The order does not change: Pellets is still largest in 2034, and what moves is how much it holds.
By Application · 7 segments
By Application
- Largest Agriculture and Crop Protection · 24%
- Fastest Urban and Public Health Control · 6.3%
- Moves most Agriculture and Crop Protection · -3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Agriculture and Crop Protection | $1.46B | 24% | $1.91B | 21%-3 | 3% |
| Livestock and Poultry Farms | $0.85B | 14% | $1.18B | 13%-1 | 3.7% |
| Residential and Household | $1.10B | 18% | $1.63B | 18% | 4.5% |
| Commercial Buildings | $0.85B | 14% | $1.36B | 15%+1 | 5.3% |
| Warehouses and Food Processing | $0.79B | 13% | $1.27B | 14%+1 | 5.4% |
| Urban and Public Health Control | $0.73B | 12% | $1.27B | 14%+2 | 6.3% |
| Conservation and Island Eradication | $0.30B | 5% | $0.45B | 5% | 4.5% |
2025 to 2034 revenue and share by line: Agriculture and Crop Protection USD 1.464 billion to USD 1.908 billion (24% to 21.01%), Residential and Household USD 1.098 billion to USD 1.634 billion (18% to 18%), Livestock and Poultry Farms USD 0.854 billion to USD 1.18 billion (14% to 13%), Commercial Buildings USD 0.854 billion to USD 1.362 billion (14% to 15%), Warehouses and Food Processing USD 0.793 billion to USD 1.271 billion (13% to 14%), Urban and Public Health Control USD 0.732 billion to USD 1.271 billion (12% to 14%), Conservation and Island Eradication USD 0.305 billion to USD 0.454 billion (5% to 5%). Agriculture and Crop Protection Led by Application in 2025, with Urban and Public Health Control Growing Fastest Agriculture and crop protection leads because farms, stores and field margins carry the largest areas needing continuous baiting. Urban and public health control grows fastest as cities densify, waste and drainage networks age, and authorities fund structured programmes. Commercial buildings and food facilities follow the same direction, driven by audit and hygiene requirements that make routine service visits standard practice. Agriculture and Crop Protection remains the largest line through 2034, so the axis changes in proportion, not in order.
By Target Species · 5 segments
Field Rodents and Voles Outpaces the Axis While Norway Rat (Rattus norvegicus) Holds the Largest Share
- Largest Norway Rat (Rattus norvegicus) · 34%
- Fastest Field Rodents and Voles · 5.5%
- Moves most Norway Rat (Rattus norvegicus) · -1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Norway Rat (Rattus norvegicus) | $2.07B | 34% | $3B | 33%-1 | 4.2% |
| Roof Rat (Rattus rattus) | $1.34B | 22% | $2B | 22% | 4.5% |
| House Mouse (Mus musculus) | $1.59B | 26% | $2.36B | 26% | 4.5% |
| Field Rodents and Voles | $0.73B | 12% | $1.18B | 13%+1 | 5.5% |
| Other Rodent Species | $0.37B | 6% | $0.55B | 6% | 4.5% |
Norway rat leads because it is the most widespread commensal pest in sewers, farms and ports and the main target of bait programmes. Field rodents and voles grow fastest, as crop damage in grain and horticulture areas rises and more growers adopt scheduled baiting. Roof rat and house mouse demand tracks building stock and food storage, so they grow near the market average. Norway Rat (Rattus norvegicus) remains the largest line through 2034, so the axis changes in proportion, not in order.
By End User · 5 segments
Professional Pest Control Operators Led by End user in 2025, with Municipal and Government Agencies Growing Fastest
- Largest Professional Pest Control Operators · 38%
- Fastest Municipal and Government Agencies · 5.6%
- Moves most Farmers and Growers · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Professional Pest Control Operators | $2.32B | 38% | $3.63B | 40%+2 | 5.1% |
| Farmers and Growers | $1.59B | 26% | $2B | 22%-4 | 2.6% |
| Households and Consumers | $0.85B | 14% | $1.27B | 14% | 4.5% |
| Municipal and Government Agencies | $0.61B | 10% | $1B | 11%+1 | 5.6% |
| Food and Industrial Facility Operators | $0.73B | 12% | $1.18B | 13%+1 | 5.5% |
Professional pest control operators lead because they buy in volume, hold the licences for restricted products and run contract programmes with repeat bait use. They also grow fastest as commercial and public customers outsource rodent control. Farmers remain a large buyer but grow slowly, since on-farm use is exposed to tighter outdoor limits and a shift toward integrated pest management. By 2034 Professional Pest Control Operators is still ahead, making this a shift in weight, not a change of leader.
By Distribution Channel · 5 segments
Agricultural and Pest Control Distributors Held the Dominant Share of the Distribution channel Segment in 2025
- Largest Agricultural and Pest Control Distributors · 36%
- Fastest Online Retail · 11.2%
- Moves most Online Retail · +6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct to Pest Control Companies | $1.34B | 22% | $2.09B | 23%+1 | 5% |
| Agricultural and Pest Control Distributors | $2.20B | 36% | $2.81B | 31%-5 | 2.8% |
| Retail Stores | $1.34B | 22% | $1.91B | 21%-1 | 4% |
| Online Retail | $0.49B | 8% | $1.27B | 14%+6 | 11.2% |
| Government Tenders | $0.73B | 12% | $1B | 11%-1 | 3.5% |
Agricultural and pest control distributors lead because they stock professional and farm packs and extend credit and technical advice to small operators. Online retail grows fastest from a small base as households and small businesses buy ready-to-use baits and stations without visiting a store. Direct sales to pest control companies gain as larger service groups consolidate purchasing. Agricultural and Pest Control Distributors remains the largest line through 2034, so the axis changes in proportion, not in order.
By Dispensing Method · 6 segments
Tamper-Resistant Bait Stations Holds the Largest Dispensing method Share and Is Still the Quickest to Grow
- Largest Tamper-Resistant Bait Stations · 38%
- Fastest Tamper-Resistant Bait Stations · 6.2%
- Moves most Tamper-Resistant Bait Stations · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Tamper-Resistant Bait Stations | $2.32B | 38% | $4B | 44%+6 | 6.2% |
| Loose Bait Placement | $0.85B | 14% | $0.91B | 10%-4 | 0.7% |
| Bait Boxes and Covered Trays | $1.10B | 18% | $1.54B | 17%-1 | 3.9% |
| Tracking Dust Application | $0.37B | 6% | $0.55B | 6% | 4.5% |
| Burrow Application and Fumigation | $0.98B | 16% | $1.36B | 15%-1 | 3.8% |
| Aerial and Broadcast Baiting | $0.49B | 8% | $0.73B | 8% | 4.5% |
Tamper-resistant bait stations lead because regulations in many markets require secured placement for outdoor and public-area use, and operators prefer them for safety and audit trails. They also grow fastest as these rules spread. Loose bait placement shrinks, since open placement carries higher risk to children, pets and wildlife and is increasingly restricted on labels. By 2034 Tamper-Resistant Bait Stations is still ahead, making this a shift in weight, not a change of leader.
By Pack Size · 3 segments
Professional Packs Holds the Largest Pack size Share and Is Still the Quickest to Grow
- Largest Professional Packs · 46%
- Fastest Professional Packs · 5.5%
- Moves most Professional Packs · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Consumer Packs | $1.46B | 24% | $2.09B | 23%-1 | 4% |
| Professional Packs | $2.81B | 46% | $4.54B | 50%+4 | 5.5% |
| Bulk Packs | $1.83B | 30% | $2.45B | 27%-3 | 3.3% |
Professional packs lead because service companies and facility operators buy in repeat quantities sized for station refills. They also grow fastest as regulation steers more rodenticide use toward trained applicators. Consumer packs hold a steady place through retail demand, while bulk packs face pressure as large-scale open baiting is limited in several jurisdictions. Professional Packs remains the largest line through 2034, so the axis changes in proportion, not in order.
By Regulatory Use Class · 5 segments
Professional-Only Use Both Leads the Regulatory use class Axis and Grows Fastest on It
- Largest Professional-Only Use · 34%
- Fastest Professional-Only Use · 5.8%
- Moves most Professional-Only Use · +4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Professional-Only Use | $2.07B | 34% | $3.45B | 38%+4 | 5.8% |
| General and Consumer Use | $1.10B | 18% | $1.54B | 17%-1 | 3.9% |
| Restricted Use Products | $0.98B | 16% | $1.45B | 16% | 4.5% |
| Indoor-Only Use | $0.61B | 10% | $0.91B | 10% | 4.5% |
| Outdoor and Agricultural Use | $1.34B | 22% | $1.73B | 19%-3 | 2.8% |
Professional-only products lead and grow fastest because regulators in major markets restrict the most potent compounds to trained and licensed users. General and consumer products lose share as limits on over-the-counter anticoagulants tighten. Outdoor and agricultural use grows slowest because outdoor placement of persistent compounds faces the strictest controls on wildlife exposure. The order does not change: Professional-Only Use is still largest in 2034, and what moves is how much it holds.
Regional Insights
North America Market Analysis
and reaches USD 1.998 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Second-Generation Anticoagulants leads here as it does globally, at 52% of 2025 revenue, and Fertility Control and Biological again grows fastest at 12.53%. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 80% of it, growing 1.3×.
- In region 1 of 3
- Of region 80%
- Of global 20%
- Revenue $1.22B → $1.60B
USD 1.22 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 1.6 billion by 2034. At 80% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 1.525 billion and USD 1.998 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in the United States follows the active ingredient type mix reported at global level: Second-Generation Anticoagulants is the largest line at 52% of 2025 revenue, moving to 48.99% by 2034, while Fertility Control and Biological grows fastest at 12.53% and takes its share from 3% to 6%. Its 80% weight in North America means those movements carry straight into the regional totals. Revenue by active ingredient type for the United States is reported separately in the full report.
Rodenticides are pesticides under the Environmental Protection Agency, which regulates them through the Federal Insecticide, Fungicide, and Rodenticide Act. Every product must be registered before sale, supported by data on efficacy, toxicity and environmental fate. The agency's risk mitigation measures for anticoagulant rodenticides add requirements on bait station use, tamper-resistant packaging and restricted channels for the most potent second-generation active ingredients. Labels must carry approved directions, first aid statements and precautionary language, and sales of restricted-use products are limited to certified applicators. State pesticide agencies add their own registration step, and several states restrict anticoagulants further.
Competition in the United States runs between the suppliers this study tracks: Bell Laboratories, Inc., Neogen Corporation, Liphatech, Inc., Syngenta AG, BASF SE, UPL Limited, Bayer AG, Envu, Rentokil Initial plc, PelGar International Ltd, Impex Europa S.L., SenesTech, Inc., Lodi Group, Killgerm Group Ltd, Sumitomo Chemical Co., Ltd., Brazil Quimica, Teikoku Seiyaku Co., Ltd., Frunol Delicia GmbH, Kwizda Agro GmbH, Ensystex, Inc., Woodstream Corporation, Ecolab Inc., Central Garden & Pet Company and Zagro Singapore Pte Ltd. The commercially relevant division is 52% of 2025 revenue in Second-Generation Anticoagulants, where the volume is, against 12.53% growth in Fertility Control and Biological, where share moves. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 1.4×.
- In region 2 of 3
- Of region 9.2%
- Of global 2.3%
- Revenue $0.14B → $0.19B
2.3% of global revenue is generated in Canada; USD 0.14 billion in 2025, reaching USD 0.19 billion in 2034, and 9.18% of North America.
Mexico
3rd-largest in North America, growing 1.5×.
- In region 3 of 3
- Of region 7.2%
- Of global 1.8%
- Revenue $0.11B → $0.16B
Within North America, Mexico accounts for 7.21% of regional revenue and 1.8% of the global total, worth USD 0.11 billion in 2025 and USD 0.16 billion by 2034.
Europe Market Analysis
and reaches USD 1.362 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Second-Generation Anticoagulants is again the largest active ingredient type line in Europe, as it is everywhere the study reports. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.2×.
- In region 1 of 3
- Of region 20.9%
- Of global 3.8%
- Revenue $0.23B → $0.27B
Germany is the largest market within Europe, generating USD 0.23 billion in 2025 and projected to reach USD 0.27 billion by 2034. Its 20.95% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 1.098 billion and USD 1.362 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The active ingredient type lines rank in Germany as they do worldwide, with Second-Generation Anticoagulants the largest line and Fertility Control and Biological gaining share fastest, so its contribution to Europe comes from scale and not from an unusual mix. Because the country carries 20.95% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Germany carries its own active ingredient type breakdown in the full report.
Rodenticides are biocidal products, so the EU Biocidal Products Regulation governs them, with the European Chemicals Agency assessing active substances and the Federal Institute for Occupational Safety and Health acting as the national authorisation body. An active substance must be approved at Union level before a product can be authorised nationally or through mutual recognition. Anticoagulant actives are treated as candidates for substitution, which brings comparative assessment and time-limited approvals. Labels must follow classification and labelling rules for hazardous mixtures. Professional-only use applies to many products, and sector codes of best practice on risk mitigation shape how suppliers market and train users.
Suppliers in Germany are the same companies covered above, Bell Laboratories, Inc. and Neogen Corporation included; none of them is specific to this market, so position here follows position on the active ingredient type axis. Two different problems sit on the same axis: holding Second-Generation Anticoagulants at 52% of 2025 revenue, and taking Fertility Control and Biological while it grows at 12.53%. A supplier weighted toward Europe is competing over a base of USD 1.098 billion in 2025, reaching USD 1.362 billion by 2034 on the trajectory this study models.
United Kingdom
2nd-largest in Europe, growing 1.2×.
- In region 2 of 3
- Of region 17.3%
- Of global 3.1%
- Revenue $0.19B → $0.23B
Within Europe, the United Kingdom accounts for 17.31% of regional revenue and 3.11% of the global total, worth USD 0.19 billion in 2025 and USD 0.225 billion by 2034.
France
3rd-largest in Europe, growing 1.2×.
- In region 3 of 3
- Of region 14.6%
- Of global 2.6%
- Revenue $0.16B → $0.19B
France is sized at USD 0.16 billion in 2025, rising to USD 0.19 billion by 2034; 2.62% of global revenue and 14.57% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
rising to USD 3.631 billion in 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Nothing in Asia Pacific's active ingredient type mix departs from the global order, so Second-Generation Anticoagulants leads here too. Asia Pacific is reported axis by axis and country by country in the full study.
China
The largest market in Asia Pacific, growing 1.7×.
- In region 1 of 3
- Of region 37.6%
- Of global 12.8%
- Revenue $0.78B → $1.35B
USD 0.78 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 1.35 billion by 2034. Its 37.61% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 2.074 billion in 2025 and USD 3.631 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Nothing about the active ingredient type mix sets China apart, with Second-Generation Anticoagulants the largest line and Fertility Control and Biological gaining share fastest exactly as at global level; the regional effect comes from how much of Asia Pacific it holds. With 37.61% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by active ingredient type for China is reported separately in the full report.
Rodenticides fall under the pesticide registration system administered by the Ministry of Agriculture and Rural Affairs, with the Institute for the Control of Agrochemicals handling technical review. Public-health rodenticides used in sanitation and disease control sit within a separate route overseen by health authorities, and suppliers should confirm which applies to a given product. Registration requires efficacy trials, toxicology and residue and environmental data, followed by a registration certificate. Production needs a licence, and labels must follow national pesticide labelling rules with toxicity class and safety warnings. Highly toxic active ingredients face prohibition or tight restriction, which narrows the permitted product range.
China has no supplier set of its own: the companies tracked for the market as a whole, Bell Laboratories, Inc. and Neogen Corporation among them, compete across its active ingredient type lines. Volume sits in Second-Generation Anticoagulants at 52% of 2025 revenue; movement sits in Fertility Control and Biological at 12.53% growth. The commercial size of that position is USD 2.074 billion in 2025, moving to USD 3.631 billion by 2034 across the forecast period.
India
2nd-largest in Asia Pacific, growing 2.2×.
- In region 2 of 3
- Of region 21.7%
- Of global 7.4%
- Revenue $0.45B → $0.98B
India is sized at USD 0.45 billion in 2025, rising to USD 0.98 billion by 2034; 7.38% of global revenue and 21.7% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Japan
3rd-largest in Asia Pacific, growing 1.3×.
- In region 3 of 3
- Of region 12.1%
- Of global 4.1%
- Revenue $0.25B → $0.33B
Japan is sized at USD 0.25 billion in 2025, rising to USD 0.33 billion by 2034; 4.1% of global revenue and 12.05% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
and reaches USD 1.09 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Buyers in Latin America take the same active ingredient type lines in the same order as the market overall, with Second-Generation Anticoagulants the largest. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 1.6×.
- In region 1 of 3
- Of region 45.1%
- Of global 5.4%
- Revenue $0.33B → $0.52B
Brazil is the largest market within Latin America, generating USD 0.33 billion in 2025 and projected to reach USD 0.52 billion by 2034. Its 45.08% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 0.732 billion in 2025 and USD 1.09 billion in 2034, it is the country the full report breaks out in detail.
Demand in Brazil follows the same active ingredient type order as the global market, with Second-Generation Anticoagulants the largest line and Fertility Control and Biological gaining share fastest, so what changes the picture here is the country's weight in Latin America, not a different mix. Since 45.08% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own active ingredient type breakdown in the full report.
Rodenticides used in agriculture are pesticides regulated by the Ministry of Agriculture, with the health agency Anvisa and the environmental agency Ibama assessing toxicology and environmental risk. Products intended for domestic or urban pest control are generally treated as sanitising products and handled by Anvisa. Registration is required before any commercial sale, supported by technical dossiers on efficacy, safety and fate. Labels and leaflets must follow national rules on toxicological classification, pictograms and use instructions. Companies that apply products professionally generally need operating authorisation from health and environmental bodies, and state agencies can add their own conditions on distribution and sale.
Brazil is contested by the same suppliers named for North America, Bell Laboratories, Inc. and Neogen Corporation among them, selling into the active ingredient type lines described above, not into a market of its own. Second-Generation Anticoagulants, at 52% of 2025 revenue, is where the volume sits, and Fertility Control and Biological, growing at 12.53%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 0.732 billion in 2025, reaching USD 1.09 billion by 2034 on the trajectory this study models.
Argentina
2nd-largest in Latin America, growing 1.3×.
- In region 2 of 3
- Of region 12.3%
- Of global 1.5%
- Revenue $0.09B → $0.12B
1.48% of global revenue is generated in Argentina; USD 0.09 billion in 2025, reaching USD 0.12 billion in 2034, and 12.3% of Latin America.
Colombia
3rd-largest in Latin America, growing 1.6×.
- In region 3 of 3
- Of region 6.8%
- Of global 0.8%
- Revenue $0.05B → $0.08B
0.82% of global revenue is generated in Colombia; USD 0.05 billion in 2025, reaching USD 0.08 billion in 2034, and 6.83% of Latin America.
Middle East and Africa Market Analysis
with USD 0.999 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.
, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The active ingredient type split here is the one described for North America, led by Second-Generation Anticoagulants. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
South Africa
The largest market in Middle East and Africa, growing 1.5×.
- In region 1 of 3
- Of region 16.4%
- Of global 1.8%
- Revenue $0.11B → $0.17B
16.39% of Middle East and Africa's base-year revenue comes from South Africa; USD 0.11 billion, rising to USD 0.17 billion by 2034. At 16.39% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 0.671 billion in 2025 and USD 0.999 billion in 2034, it is the country the full report breaks out in detail.
South Africa buys the active ingredient type lines in the global order, with Second-Generation Anticoagulants the largest line and Fertility Control and Biological gaining share fastest; the country's size in the region is the figure that matters here. Since 16.39% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports South Africa by active ingredient type separately.
Rodenticides are regulated as agricultural remedies under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, administered by the Department of Agriculture, Land Reform and Rural Development. A product must be registered before it is imported, manufactured or sold, and the registration holder must be a local entity. Applications include efficacy, toxicity and residue information, and labels must carry the approved wording, registration number and safety directions. Where products are sold for public-health pest control, the Hazardous Substances Act and the Department of Health also have a role. Pest control operators generally need to be registered with the relevant authority.
The supplier field in South Africa is the one this study tracks globally, led by names such as Bell Laboratories, Inc. and Neogen Corporation, and they compete here on the same active ingredient type lines. Two different problems sit on the same axis: holding Second-Generation Anticoagulants at 52% of 2025 revenue, and taking Fertility Control and Biological while it grows at 12.53%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.671 billion in 2025, reaching USD 0.999 billion by 2034 on the trajectory this study models.
Egypt
2nd-largest in Middle East and Africa, growing 1.6×.
- In region 2 of 3
- Of region 14.9%
- Of global 1.6%
- Revenue $0.10B → $0.16B
Egypt is sized at USD 0.1 billion in 2025, rising to USD 0.16 billion by 2034; 1.64% of global revenue and 14.9% of Middle East and Africa. It is reported separately from South Africa across every segmentation axis in the full report.
Saudi Arabia
3rd-largest in Middle East and Africa, growing 1.7×.
- In region 3 of 3
- Of region 13.4%
- Of global 1.5%
- Revenue $0.09B → $0.15B
1.48% of global revenue is generated in Saudi Arabia; USD 0.09 billion in 2025, reaching USD 0.15 billion in 2034, and 13.41% of Middle East and Africa.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by active ingredient type, form, application, target species, end user, distribution channel, dispensing method, pack size, regulatory use class, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Second-Generation Anticoagulants and Growth in Fertility Control and Biological Set the Terms of Competition
The field covered here is Bell Laboratories, Inc., Neogen Corporation, Liphatech, Inc., Syngenta AG, BASF SE, UPL Limited, Bayer AG, Envu, Rentokil Initial plc, PelGar International Ltd, Impex Europa S.L., SenesTech, Inc., Lodi Group, Killgerm Group Ltd, Sumitomo Chemical Co., Ltd., Brazil Quimica, Teikoku Seiyaku Co., Ltd., Frunol Delicia GmbH, Kwizda Agro GmbH, Ensystex, Inc., Woodstream Corporation, Ecolab Inc., Central Garden & Pet Company and Zagro Singapore Pte Ltd.
Competition follows the active ingredient type split, not the regional one. The largest block of revenue is Second-Generation Anticoagulants: USD 3.172 billion in 2025 at 52% of the total, 48.99% in 2034. Incumbency there is expensive to challenge. Fertility Control and Biological, compounding at 12.53% against 0.5% for First-Generation Anticoagulants, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 6.1 billion.
Formulation know-how and access to active ingredients separate suppliers first: companies that make or secure second-generation anticoagulants and newer non-anticoagulant actives can keep bait palatable and supplied. Product registrations in each country are a second barrier, since renewals and data requirements are costly. The largest players add distributor reach, professional brands that service technicians specify, and global supply continuity. Smaller and regional suppliers compete on local registrations, price, private-label bait for pest control chains and quick response to local resistance patterns. Stewardship training and tamper-resistant station systems also tie professional customers to a supplier's range.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Rodenticides Market Companies Profiled
24 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Bell Laboratories, Inc.(United States)
- Neogen Corporation(United States)
- Liphatech, Inc.(United States)
- Syngenta AG(Switzerland)
- BASF SE(Germany)
- UPL Limited(India)
- Bayer AG(Germany)
- Envu(Germany)
- Rentokil Initial plc(United Kingdom)
- PelGar International Ltd(United Kingdom)
- Impex Europa S.L.(Spain)
- SenesTech, Inc.(United States)
- Lodi Group(France)
- Killgerm Group Ltd(United Kingdom)
- Sumitomo Chemical Co., Ltd.(Japan)
- Brazil Quimica(Brazil)
- Teikoku Seiyaku Co., Ltd.(Japan)
- Frunol Delicia GmbH(Germany)
- Kwizda Agro GmbH(Austria)
- Ensystex, Inc.(United States)
- Woodstream Corporation(United States)
- Ecolab Inc.(United States)
- Central Garden & Pet Company(United States)
- Zagro Singapore Pte Ltd(Singapore)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 9 axes (Active Ingredient Type, Form, Application, Target Species, End User, Distribution Channel, Dispensing Method, Pack Size, Regulatory Use Class), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 24 key companies, and the research methodology behind every estimate.
Segmentation
9 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Rodenticides Market projected to reach?
USD 9.08 USD Billion by 2034, CAGR 4.53%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which segment leads the market?
Second-Generation Anticoagulants is the largest line by active ingredient type, at 52% of revenue in 2025.
05Who are the key companies profiled?
Bell Laboratories, Inc., Neogen Corporation, Liphatech, Inc., Syngenta AG, BASF SE, UPL Limited, Bayer AG, Envu, Rentokil Initial plc, PelGar International Ltd, Impex Europa S.L., SenesTech, Inc., Lodi Group, Killgerm Group Ltd, Sumitomo Chemical Co., Ltd., Brazil Quimica, Teikoku Seiyaku Co., Ltd., Frunol Delicia GmbH, Kwizda Agro GmbH, Ensystex, Inc., Woodstream Corporation, Ecolab Inc., Central Garden & Pet Company, Zagro Singapore Pte Ltd. Full profiles are part of the paid report.
06Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.